23 May 2013
Keywords: astrazeneca, iressa, shows, promise, non-small, cell, lung
Article | 02 November 2001
Preliminary data from the first pivotal Phase II trial of AstraZeneca'stargeted cancer drug Iressa (ZD1839) indicate that, when used as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 November 2001
1 November 2001
22 May 2013
© 2013 thepharmaletter.com